Wuhan Easy Diagnosis Biomedicine Co.,Ltd.’s Net Profit Rose 285.2% in First Three Quarters of 2022

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (武汉明德生物科技股份有限公司) (002932.SZ) reported a net profit of 4 billion yuan in the first three quarters of 2022, up 285.2% year-on-year.

Meanwhile, the company posted 7.5 billion yuan in revenue, up 285.4% year-on-year.

At the end of the reporting period, it had 7.5 billion yuan in total assets and 1.1 billion yuan in total liabilities, with a liability-to-asset ratio of 15.2%.